CSTL vs. FLGT, CDNA, VRDN, SERA, BDSX, PSNL, RNLX, XGN, DMTK, and VCYT
Should you be buying Castle Biosciences stock or one of its competitors? The main competitors of Castle Biosciences include Fulgent Genetics (FLGT), CareDx (CDNA), Viridian Therapeutics (VRDN), Sera Prognostics (SERA), Biodesix (BDSX), Personalis (PSNL), Renalytix (RNLX), Exagen (XGN), DermTech (DMTK), and Veracyte (VCYT). These companies are all part of the "medical laboratories" industry.
Fulgent Genetics (NASDAQ:FLGT) and Castle Biosciences (NASDAQ:CSTL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, community ranking, institutional ownership and dividends.
Fulgent Genetics has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500. Comparatively, Castle Biosciences has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500.
Castle Biosciences has lower revenue, but higher earnings than Fulgent Genetics. Castle Biosciences is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Fulgent Genetics had 2 more articles in the media than Castle Biosciences. MarketBeat recorded 4 mentions for Fulgent Genetics and 2 mentions for Castle Biosciences. Fulgent Genetics' average media sentiment score of 1.43 beat Castle Biosciences' score of 0.89 indicating that Castle Biosciences is being referred to more favorably in the news media.
48.1% of Fulgent Genetics shares are owned by institutional investors. Comparatively, 92.6% of Castle Biosciences shares are owned by institutional investors. 32.7% of Fulgent Genetics shares are owned by insiders. Comparatively, 7.2% of Castle Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Fulgent Genetics received 163 more outperform votes than Castle Biosciences when rated by MarketBeat users. However, 62.31% of users gave Castle Biosciences an outperform vote while only 60.70% of users gave Fulgent Genetics an outperform vote.
Castle Biosciences has a net margin of -12.28% compared to Castle Biosciences' net margin of -57.72%. Castle Biosciences' return on equity of -2.92% beat Fulgent Genetics' return on equity.
Fulgent Genetics currently has a consensus target price of $30.00, indicating a potential upside of 40.25%. Castle Biosciences has a consensus target price of $31.57, indicating a potential upside of 29.55%. Given Castle Biosciences' higher possible upside, equities research analysts clearly believe Fulgent Genetics is more favorable than Castle Biosciences.
Summary
Fulgent Genetics and Castle Biosciences tied by winning 9 of the 18 factors compared between the two stocks.
Get Castle Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for CSTL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CSTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Castle Biosciences Competitors List
Related Companies and Tools
